OncoTargets and Therapy (Sep 2019)
Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
Abstract
Xin Chen1,2, Yazhou Zhang1,2, Nu Zhang1,2, Yongsheng Ge1,2, Weidong Jia1,2 1Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230001, People’s Republic of China; 2Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui Province 230001, People’s Republic of ChinaCorrespondence: Weidong JiaDepartment of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, No.17, Lu Jiang Road, Hefei, Anhui Province 230001, People’s Republic of ChinaTel +86 551 6228 3740Fax +86 551 6228 3740Email [email protected]: Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient’s condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer.Keywords: HCC, lenvatinib, nivolumab injection, hepatectomy, combination therapy
